HERON THERAPEUTICS, INC. /DE/ Operating Lease, Expense
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Operating Lease, Expense of $3.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-26
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for the quarter ending 2020-12-31 was $1.00M, a 25.00% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for the quarter ending 2020-09-30 was $900.00K, a 50.00% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for the quarter ending 2020-06-30 was $1.00M, a 25.00% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for the quarter ending 2020-03-31 was $1.00M, a 11.11% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for fiscal 2025 was $3.10M, a 3.33% increase from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for fiscal 2024 was $3.00M, a 3.45% increase from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for fiscal 2023 was $2.90M, a 3.57% increase from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ operating lease, expense for fiscal 2022 was $2.80M, a 24.32% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.10M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $3.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $2.90M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $2.80M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $3.70M 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.90M derived: sum of 2 quarters · filed 2022-02-28 | $2.90M derived: sum of 3 quarters · filed 2022-02-28 | $3.90M 10-K · filed 2022-02-28 |
| 2020-09-30 | $900.00K 10-Q · filed 2020-11-05 | $1.90M derived: sum of 2 quarters · filed 2020-11-05 | $2.90M 10-Q · filed 2020-11-05 | $3.70M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-05 | $2.00M 10-Q · filed 2020-08-05 | $2.80M derived: sum of 3 quarters · filed 2022-02-28 | $3.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-06 | $1.80M derived: sum of 2 quarters · filed 2022-02-28 | $2.40M derived: sum of 3 quarters · filed 2022-02-28 | $3.20M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.40M derived: sum of 2 quarters · filed 2022-02-28 | $2.20M derived: sum of 3 quarters · filed 2022-02-28 | $3.10M 10-K · filed 2022-02-28 |
| 2019-09-30 | $600.00K 10-Q · filed 2019-11-12 | $1.40M derived: sum of 2 quarters · filed 2019-11-12 | $2.30M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $800.00K 10-Q · filed 2019-08-05 | $1.70M 10-Q · filed 2019-08-05 | ||
| 2019-03-31 | $900.00K 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $3.20M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $3.10M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |